Journal of Korean Society for Clinical Pharmacology and Therapeutics (임상약리학회지)
- Volume 13 Issue 2
- /
- Pages.121-133
- /
- 2005
- /
- 1225-5467(pISSN)
Signal Detection and Causality Evaluation for Pharmacovigilance
약물감시를 위한 실마리정보 파악 및 인과관계 평가
- Lee, Seung-Mi (Department of Preventive Medicine, Seoul National University College of Medicine,Medical Research Collaborating Center, Seoul National University College of Medicine/Seoul National University Hospital) ;
- Hahn, Seo-Kyung (Medical Research Collaborating Center, Seoul National University College of Medicine/Seoul National University Hospital) ;
- Park, Byung-Joo (Department of Preventive Medicine, Seoul National University College of Medicine,Medical Research Collaborating Center, Seoul National University College of Medicine/Seoul National University Hospital,Clinical Research Center, Seoul National University Hospital)
- 이승미 (서울대학교 의과대학 예방의학교실,서울대학교 의과대학/서울대학교병원 의학연구협력센터) ;
- 한서경 (서울대학교 의과대학/서울대학교병원 의학연구협력센터) ;
- 박병주 (서울대학교 의과대학 예방의학교실,서울대학교 의과대학/서울대학교병원 의학연구협력센터,서울대학교병원 임상시험센터)
- Published : 2005.12.30
Abstract
Pharmacovigilance is the science and activities relating to detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems. Information sources for pharmacovigilance could be premarketing or postmarketing data from pre-clinical experiments, clinical trials, spontaneous reports, large automated databases, pharmacoepidemiologic studies, and meta-analysis studies. Spontaneous reporting data playa key role to identify signals for marketed drugs. Steps in the spontaneous adverse event signaling process consist of signal detection phase and signal evaluation phase, and involve various statistical methods. Through record linkage of large existing automated databases by individual identifiers, it is possible to conduct longitudinal researches on drug safety issues in large population. Carefully designed and conducted pharmacoepidemiologic studies are important tools in pharmacovigilance. Case-control studies and cohort studies are widely used to confirm the causality between drugs and adverse events. In this paper, we discussed possible data sources for pharmacovigilance and introduced some useful methodological approaches. Evidence-based decisions through these methods should be effectively distributed to healthcare professionals, patients and media.